伊戈爾(002922.SZ):擬設立新加坡子公司 作為海外貿易平台及海外投資控股平台
格隆匯 11 月 9日丨伊戈爾(002922.SZ)公佈,為進一步深入推進公司國際化戰略佈局,公司擬使用自有資金2700萬新加坡元在新加坡投資設立全資子公司。此次對外投資屬於董事會審批權限,無需提交股東大會審議。
此次擬在新加坡設立全資子公司,是公司基於未來國際化發展戰略的重要佈局,在新加坡設立全資子公司可充分利用新加坡的國際貿易和國際金融等方面的優勢深入實施公司全球化發展戰略,公司計劃將擬設立的新加坡子公司作為海外貿易平台及海外投資控股平台,以提高公司核心競爭力,符合公司長遠發展利益。同時憑藉新加坡子公司的地理位置優勢,公司能夠更好地開拓海外市場與服務客户。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.